Novagali Pharma receives US FDA Orphan Drug Designation for Vekacia for the treatment of Vernal Keratoconjunctivitis

Novagali Pharma, an emerging ophthalmic pharmaceutical company, announced on May 25th that orphan drug designation granted by the U.S. Food and Drug Administration (FDA) to Cyclosporine A drug Vekacia®, a patented cationic emulsion, for the treatment of Vernal Keratoconjunctivitis (VKC).